Select Publications

Journal articles

Brew BJ; McArthur J, 2019, 'Distinguishing cognitive impairment from HIV-associated neurocognitive disorder versus substance use?', AIDS, vol. 33, pp. 1943 - 1944,

Brew BJ; Paul R, 2019, 'HIV-associated neurocognitive disorder, extracellular vesicles and gender: Vive la difference?', AIDS, vol. 33, pp. 1795 - 1796,

Chaganti J; Marripudi K; Staub LP; Rae CD; Gates TM; Moffat KJ; Brew BJ, 2019, 'Imaging correlates of the blood-brain barrier disruption in HIV-associated neurocognitive disorder and therapeutic implications', AIDS, vol. 33, pp. 1843 - 1852,

Jacobs KR; Lim CK; Blennow K; Zetterberg H; Chatterjee P; Martins RN; Brew BJ; Guillemin GJ; Lovejoy DB, 2019, 'Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau', Neurobiology of Aging, vol. 80, pp. 11 - 20,

Aung HL; Kootar S; Gates TM; Brew BJ; Cysique LA, 2019, 'How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection?', European Geriatric Medicine, vol. 10, pp. 227 - 238,

Cysique LA; Brew BJ, 2019, 'Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm', Journal of NeuroVirology,

Cysique LA; Jugé L; Lennon MJ; Gates TM; Jones SP; Lovelace MD; Rae CD; Johnson TP; Nath A; Brew BJ, 2019, 'HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infection', AIDS, vol. 33, pp. 433 - 441,

Asahchop EL; Branton WG; Krishnan A; Chen PA; Yang D; Kong L; Zochodne DW; Brew BJ; Gill MJ; Power C, 2018, 'HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction', JCI insight, vol. 3,

Sutherland EJ; Brew BJ, 2018, 'Human Immunodeficiency Virus and the Nervous System', Neurologic Clinics, vol. 36, pp. 751 - 765,

Wilson MR; O'Donovan BD; Gelfand JM; Sample HA; Chow FC; Betjemann JP; Shah MP; Richie MB; Gorman MP; Hajj-Ali RA; Calabrese LH; Zorn KC; Chow ED; Greenlee JE; Blum JH; Green G; Khan LM; Banerji D; Langelier C; Bryson-Cahn C; Harrington W; Lingappa JR; Shanbhag NM; Green AJ; Brew BJ; Soldatos A; Strnad L; Doernberg SB; Jay CA; Douglas V; Josephson SA; DeRisi JL, 2018, 'Chronic meningitis investigated via metagenomic next-generation sequencing', JAMA Neurology, vol. 75, pp. 947 - 955,

Nichols M; Gates T; Soares J; Moffat K; Rae C; Brew B; Cysique L, 2018, 'Brain atrophic signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection', AIDS, vol. 33, pp. 55 - 66,

Wright EJ; Grund B; Robertson KR; Cysique L; Brew BJ; Collins GL; Poehlman-Roediger M; Vjecha MJ; Penalva De Oliveira AC; Standridge B; Carey C; Avihingsanon A; Florence E; Lundgren JD; Arenas-Pinto A; Mueller NJ; Winston A; Nsubuga MS; Lal L; Price RW, 2018, 'No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts', AIDS, vol. 32, pp. 985 - 997,

Brew BJ; Garber JY, 2018, 'Neurologic sequelae of primary HIV infection', Handbook of Clinical Neurology, vol. 152, pp. 65 - 74,

Smail RC; Brew BJ, 2018, 'HIV-associated neurocognitive disorder', Handbook of Clinical Neurology, vol. 152, pp. 75 - 97,

Brew BJ, 2018, 'Introduction to HIV infection and HIV neurology', Handbook of Clinical Neurology, vol. 152, pp. 1 - 2,

Zhai S; Brew BJ, 2018, 'Progressive multifocal leukoencephalopathy', Handbook of Clinical Neurology, vol. 152, pp. 123 - 137,

Warhurst S; Rofe CJ; Brew BJ; Bateson D; McGeechan K; Merki-Feld GS; Garrick R; Tomlinson SE, 2018, 'Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis', Cephalalgia, vol. 38, pp. 754 - 764,

Anderson AM; Croteau D; Ellis RJ; Rosario D; Potter M; Guillemin GJ; Brew BJ; Woods SP; Letendre SL, 2018, 'HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau', Journal of Neuroimmunology, vol. 319, pp. 13 - 18,

Cysique LA; Jugé L; Gates T; Tobia M; Moffat K; Brew BJ; Rae C, 2018, 'Covertly active and progressing neurochemical abnormalities in suppressed HIV infection', Neurology: Neuroimmunology and NeuroInflammation, vol. 5,

Radd-Vagenas S; Duffy SL; Naismith SL; Brew BJ; Flood VM; Fiatarone Singh MA, 2018, 'Effect of the Mediterranean diet on cognition and brain morphology and function: A systematic review of randomized controlled trials', American Journal of Clinical Nutrition, vol. 107, pp. 389 - 404,

Bundell C; Brunt SJ; Cysique LA; Brusch A; Brew BJ; Price P, 2018, 'The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy', Pathology, vol. 50, pp. 313 - 316,

Haggstrom L; Brew B; Sutton I; Tisch S, 2018, 'Vestibular symptoms as the presenting feature of progressive supranuclear palsy', Journal of Clinical Neuroscience, vol. 50, pp. 74 - 76,

Chaganti JR; Heinecke A; Gates TM; Moffat KJ; Brew BJ, 2017, 'Functional connectivity in virally suppressed patients with HIV-associated neurocognitive disorder: A resting-state analysis', American Journal of Neuroradiology, vol. 38, pp. 1623 - 1629,

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration (Journal of NeuroVirology, (2017), 23, 4, (539-547), 10.1007/s13365-017-0524-1)', Journal of NeuroVirology, vol. 23, pp. 548 - 549,

Brew BJ; Cysique L, 2017, 'Does HIV prematurely age the brain?', The Lancet HIV, vol. 4, pp. e380 - e381,

Bukhari W; Prain KM; Waters P; Woodhall M; O'Gorman CM; Clarke L; Silvestrini RA; Bundell CS; Abernethy D; Bhuta S; Blum S; Boggild M; Boundy K; Brew BJ; Brown M; Brownlee WJ; Butzkueven H; Carroll WM; Chen C; Coulthard A; Dale RC; Das C; Dear K; Fabis-Pedrini MJ; Fulcher D; Gillis D; Hawke S; Heard R; Henderson APD; Heshmat S; Hodgkinson S; Jimenez-Sanchez S; Killpatrick T; King J; Kneebone C; Kornberg AJ; Lechner-Scott J; Lin MW; Lynch C; Macdonell R; Mason DF; McCombe PA; Pender MP; Pereira JA; Pollard JD; Reddel SW; Shaw C; Spies J; Stankovich J; Sutton I; Vucic S; Walsh M; Wong RC; Yiu EM; Barnett MH; Kermode AG; Marriott MP; Parratt JDE; Slee M; Taylor BV; Willoughby E; Wilson RJ; Vincent A; Broadley SA, 2017, 'Incidence and prevalence of NMOSD in Australia and New Zealand', Journal of Neurology, Neurosurgery and Psychiatry, vol. 88, pp. 632 - 638,

Lennon MJ; Jones SP; Lovelace MD; Guillemin GJ; Brew BJ, 2017, 'Bcl11b-A critical neurodevelopmental transcription factor-roles in health and disease', Frontiers in Cellular Neuroscience, vol. 11,

Brew B; Carroll A, 2017, 'HIV-associated neurocognitive disorders: Recent advances in pathogenesis, biomarkers, and treatment', F1000Research, vol. 6,

Cysique LA; Soares JR; Geng G; Scarpetta M; Moffat K; Green M; Brew BJ; Henry RG; Rae C, 2017, 'White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration', Journal of NeuroVirology, vol. 23, pp. 539 - 547,

Cysique LA; Gott C; Gates TM; Dermody N; Brew BJ, 2017, 'Cognitive Change Trajectories in Virally Suppressed HIV-Infected Individuals Indicate High Prevalence of Disease Activity', PLoS One, vol. 12,

Kamminga J; Lal L; Wright EJ; Bloch M; Brew BJ; Cysique LA, 2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV/AIDS Reports, vol. 14, pp. 83 - 92,

Gott C; Gates T; Dermody N; Brew BJ; Cysique LA, 2017, 'Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity', PLOS ONE, vol. 12,

Lim CK; Bilgin A; Lovejoy DB; Tan V; Bustamante S; Taylor BV; Bessede A; Brew BJ; Guillemin GJ, 2017, 'Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression', Scientific Reports, vol. 7,

Ellero J; Lubomski M; Brew B, 2017, 'Interventions for Neurocognitive Dysfunction', Current HIV/AIDS Reports, vol. 14, pp. 8 - 16,

Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA, 2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, vol. 39, pp. 753 - 767,

Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ, 2017, 'Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis', Neuropharmacology, vol. 112, pp. 346 - 364,

Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ, 2017, 'Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases', Neuropharmacology, vol. 112, pp. 373 - 388,

Anesten B; Yilmaz A; Hagberg L; Zetterberg H; Nilsson S; Brew BJ; Fuchs D; Price RW; Gisslén M, 2016, 'Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV', Neurology: Neuroimmunology and NeuroInflammation, vol. 3,

Tobia M; Jones S; Lovelace M; Rae C; Cysique L; Brew B, 2016, 'Reduced cellular energy as a potential marker of HIV brain latency related neuropathogenesis: a pilot study', JOURNAL OF NEUROVIROLOGY, vol. 22, pp. S76 - S77,

Bloch M; Kamminga J; Jayewardene A; Bailey M; Carberry A; Vincent T; Quan D; Maruff P; Brew B; Cysique LA, 2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, vol. 63, pp. 687 - 693,

Nadel J; O'Dwyer E; Emmanuel S; Huang J; Cheruvu S; Sammel N; Brew B; Otton J; Holloway CJ, 2016, 'High-risk coronary plaque, invasive coronary procedures, and cardiac events among HIV-positive individuals and matched controls', Journal of Cardiovascular Computed Tomography, vol. 10, pp. 391 - 397,

Lovelace MD; Varney B; Sundaram G; Franco NF; Ng ML; Pai S; Lim CK; Guillemin GJ; Brew BJ, 2016, 'Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis', Frontiers in Immunology, vol. 7,

Brew BJ, 2016, 'Has HIV-associated neurocognitive disorders now transformed into vascular cognitive impairment?', AIDS, vol. 30, pp. 2379 - 2380,

Braidy N; Rossez H; Lim CK; Jugder BE; Brew BJ; Guillemin GJ, 2016, 'Characterization of the Kynurenine Pathway in CD8+ Human Primary Monocyte-Derived Dendritic Cells', Neurotoxicity Research, vol. 30, pp. 620 - 632,

Walker S; Brew B, 2016, 'Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis', Journal of Clinical Neuroscience, vol. 31, pp. 217 - 218,

Brunt SJ; Cysique LA; Lee S; Burrows S; Brew BJ; Price P, 2016, 'Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?', AIDS Research and Human Retroviruses, vol. 32, pp. 567 - 572,

Gray LR; Brew BJ; Churchill MJ, 2016, 'Strategies to target HIV-1 in the central nervous system', Current Opinion in HIV and AIDS, vol. 11, pp. 371 - 375,

Gates TM; Cysique LA; Siefried KJ; Chaganti J; Moffat KJ; Brew BJ, 2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, vol. 30, pp. 591 - 600,

Cysique LA; Dermody N; Carr A; Brew BJ; Teesson M, 2016, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, vol. 22, pp. 56 - 65,

Crossley KM; Agnihotri S; Chaganti J; Rodriguez ML; McNally LP; Venna N; Turbett SE; Gutman M; Morey A; Koralnik IJ; Brew BJ, 2016, 'Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals', Journal of NeuroVirology, vol. 22, pp. 541 - 545,

Back to profile page